612 Ovarian Cancer Clinical Trials Recruiting Now (July 2026): BRCA, HRD, PARP, FRα, ADC, HGSOC
Last updated: July 1, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- PARP inhibitors (58 trials): beyond maintenance — non-HRD combinations, re-challenge, PARP + angiogenesis
- ADCs (34 trials): mirvetuximab soravtansine (FRα), AZD5335 (FRα), Rina-S (TROP2), Sac-TMT (TROP2), T-DXd (HER2), raludotatug deruxtecan, sofetabart mipitecan, IBI354, SHR-A1921, BL-B01D1 (EGFR×HER3)
- Checkpoint immunotherapy (48 trials): PD-1/PD-L1 ± bevacizumab combinations, including PD-1/CTLA-4 bispecifics for clear cell histology
- Biomarker-selected agents: CCNE1/Cyclin E1 (INCB123667, azenosertib), HER2 expression (T-DXd), HRD-positive (PARP combos)
- MEK + FAK inhibitors for recurrent low-grade serous; HIPEC and minimally invasive surgery trials
Already approved: Olaparib (Lynparza), niraparib (Zejula), rucaparib (PARP), bevacizumab, mirvetuximab soravtansine (FRα+ platinum-resistant)
Recruiting Trials by Treatment Setting
First-Line Maintenance (After Platinum Response)
PARP inhibitors ± bevacizumab are standard maintenance. Trials test new combinations and non-HRD strategies:
- NCT07472140 - PARP inhibitor ± angiogenesis inhibitor in HRD-positive primary ovarian cancer (Phase 3)
- NCT06580314 - Olaparib for 1 vs 2 years ± Bevacizumab (Phase 3)
- NCT06819007 - DESTINY-Ovarian01: T-DXd + Bevacizumab vs Bevacizumab maintenance in HER2-expressing (Phase 3)
- NCT07318558 - Sacituzumab Tirumotecan (MK-2870) in non-HRD positive advanced ovarian cancer (Phase 3)
Platinum-Sensitive Recurrence
- NCT07225270 - Rina-S (ADC) + SOC vs SOC for maintenance after 2L platinum-based chemo (Phase 3)
- NCT07564141 - Rina-S ± Bevacizumab vs platinum-based chemo ± Bevacizumab as 2L treatment in platinum-sensitive recurrence (Phase 3, not-yet-recruiting)
- NCT06824467 - Sacituzumab Tirumotecan (MK-2870) maintenance vs SOC in platinum-sensitive recurrence (Phase 3)
- NCT07213804 - Sofetabart Mipitecan (ADC) in platinum-sensitive ovarian cancer (Phase 3, Part B)
- NCT05009082 - Niraparib vs Niraparib + Bevacizumab after platinum/taxane chemo (Phase 3)
- NCT05255471 - MITO 35B: Olaparib beyond progression vs platinum chemo after secondary cytoreduction (Phase 3)
Platinum-Resistant / Refractory
Major unmet need. ADCs and novel agents are transforming this space:
- ADCs:
- NCT07218809 - AZD5335 vs Mirvetuximab (FRα-high) and AZD5335 vs Chemo (FRα-low) in platinum-resistant (Phase 3)
- NCT06161025 - Raludotatug Deruxtecan (R-DXd) in platinum-resistant high-grade ovarian cancer (Phase 3)
- NCT06834672 - IBI354 vs Chemo in platinum-resistant ovarian cancer (Phase 3)
- NCT06394492 - SHR-A1921 in platinum-resistant recurrent EOC (Phase 3)
- NCT06828354 - SHR-A1811 (T-DXd analog) in ovarian cancer (Phase 3)
- NCT06994195 - BL-B01D1 (EGFR×HER3 bispecific ADC) vs Chemo in platinum-resistant (Phase 3)
- NCT07286266 - BEHOLD-Ovarian01: Mocertatug Rezetecan vs SOC in platinum-resistant (Phase 3, not-yet-recruiting)
- NCT07604766 - Rina-S extension study in platinum-resistant ovarian cancer in China (Phase 3, not-yet-recruiting)
- Biomarker-selected agents (CCNE1 / Cyclin E1):
- NCT07214779 - INCB123667 vs Chemo in platinum-resistant with Cyclin E1 overexpression (Phase 3)
- NCT07546500 - Azenosertib (ZN-c3, WEE1 inhibitor) vs Chemo in platinum-resistant HGSOC with Cyclin E1-positive expression (Phase 3)
- Other novel agents:
- NCT05281471 - OnPrime: Olvi-Vec (oncolytic virus) + platinum-doublet + bevacizumab vs Chemo + Bevacizumab (Phase 3)
- NCT04921527 - Chiauranib + weekly paclitaxel in platinum-resistant recurrence (Phase 3)
Surgery & Perioperative
- NCT04575935 - LANCE: Minimally invasive surgery after NACT for stage IIIC-IV (Phase 3)
- NCT05827523 - FOCUS: Interval cytoreductive surgery ± HIPEC (Phase 3)
- NCT06915025 - IMNN-001 + standard NACT and adjuvant chemo in newly diagnosed advanced EOC (Phase 3)
Specific Histologies
- Low-grade serous (LGSOC):
- NCT06072781 - Avutometinib (MEKi) + Defactinib (FAKi) in recurrent LGSOC (Phase 3)
- NCT05601700 - LEPRE: Letrozole for ER/PR-positive LGSOC (Phase 3)
- Clear cell carcinoma:
- NCT07002346 - INVIGORATE: QL1706 (PD-1/CTLA-4 bispecific) + Bevacizumab in first-line advanced ovarian clear cell carcinoma (Phase 3)
- Early-stage:
- NCT04063527 - Stage I ovarian cancer after surgery (Phase 3)
Novel Approaches
- Next-gen ADCs: Raludotatug deruxtecan (R-DXd, B7-H4-targeted), sofetabart mipitecan, IBI354, SHR-A1921, Rina-S (FRα-targeted) — multiple new ADCs racing to improve on mirvetuximab in platinum-resistant disease, with Rina-S now extending into platinum-sensitive 2L (NCT07564141)
- Non-HRD maintenance: Sacituzumab tirumotecan (Sac-TMT) and T-DXd — extending maintenance beyond BRCA/HRD patients (NCT07318558, NCT06824467, NCT06819007)
- Cyclin E1 / CCNE1-selected: INCB123667 and azenosertib (WEE1 inhibitor) for platinum-resistant ovarian cancer with CCNE1 amplification / Cyclin E1 protein overexpression — biomarker-selected Phase 3s (NCT07214779, NCT07546500)
- PD-1/CTLA-4 bispecifics in clear cell: QL1706 + bevacizumab for first-line clear cell carcinoma (INVIGORATE, NCT07002346) — a histology with poor PARP-i and chemotherapy response
- HER2-directed in HGSOC: T-DXd + bevacizumab maintenance for HER2-expressing first-line ovarian cancer (DESTINY-Ovarian01, NCT06819007); see trastuzumab deruxtecan drug page for cross-tumor evidence
- Oncolytic virus: Olvi-Vec combined with platinum chemotherapy for platinum-resistant disease (OnPrime, NCT05281471)
- Personalized vaccines: NCT06341907 - MRD + personalized vaccine for recurrence prevention after EOC surgery
- IL-12 gene therapy: IMNN-001 + standard NACT + adjuvant chemo in newly diagnosed advanced EOC (OVATION-2 / NCT06915025)
Frequently Asked Questions
How do I find ovarian cancer clinical trials?
Paste your medical summary into ClinTrialFinder to get AI-matched ovarian cancer trials in minutes. The tool considers your BRCA1/2 status, HRD score, folate receptor alpha (FRα) expression, HER2 expression, CCNE1/Cyclin E1 status, histology (high-grade serous, clear cell, low-grade serous, endometrioid), platinum sensitivity, and prior treatments.
What ovarian cancer trials are currently recruiting?
There are 612 recruiting interventional trials for ovarian cancer in July 2026, including PARP inhibitors, next-generation ADCs (mirvetuximab soravtansine FRα, raludotatug deruxtecan CDH6, sacituzumab tirumotecan/Sac-TMT MK-2870-021 non-HRD Phase 3 — see TROP2 ADCs hub, Rina-S, AZD5335, IBI354), HER2-directed T-DXd — see HER2 ADCs hub, checkpoint immunotherapy combinations, and biomarker-selected agents for platinum-resistant disease including Cyclin E1 inhibitors (INCB123667, azenosertib) and bispecific ADCs.
What trials are open for platinum-resistant ovarian cancer?
Platinum-resistant ovarian cancer (PROC) is one of the most active research areas. Recruiting Phase 3 options include FRα-targeted ADCs (AZD5335 vs mirvetuximab in NCT07218809), next-gen TOPO-1 ADCs (Sofetabart Mipitecan NCT07213804, IBI354 NCT06834672, SHR-A1921 NCT06394492), Rina-S in second-line (NCT07564141), Raludotatug Deruxtecan (NCT06161025), HER3/EGFR bispecific ADC BL-B01D1 (NCT06994195), Cyclin E1-selected agents INCB123667 (NCT07214779) and azenosertib (NCT07546500), and oncolytic-virus combinations (Olvi-Vec, NCT05281471).
Which ovarian cancer trials match BRCA1/2 mutations or HRD-positive status?
BRCA1/2-mutated or HRD-positive ovarian cancer remains the most PARP-inhibitor sensitive setting (see the PARP Inhibitors mechanism hub for the full class — Lynparza/olaparib + Zejula/niraparib + Rubraca/rucaparib FDA-approved + saruparib next-gen). Phase 3 trials currently recruiting include PARP ± angiogenesis inhibitor in HRD-positive primary disease (NCT07472140), olaparib 1 vs 2 years ± bevacizumab (NCT06580314), niraparib ± bevacizumab maintenance (NCT05009082), olaparib beyond progression after secondary cytoreduction (MITO 35B, NCT05255471), and Sac-TMT maintenance in non-HRD patients (NCT07318558) for patients without HRD.
Are there trials specific to low-grade serous, clear cell, or other histologies?
Yes. For low-grade serous ovarian cancer (LGSOC), recruiting Phase 3 trials include avutometinib (MEK) + defactinib (FAK) (NCT06072781) and letrozole maintenance in ER/PR-positive disease (LEPRE, NCT05601700). For ovarian clear cell carcinoma, the INVIGORATE Phase 3 (NCT07002346) is testing QL1706 (PD-1/CTLA-4 bispecific) + bevacizumab in first-line advanced disease. For HER2-expressing high-grade serous, DESTINY-Ovarian01 (NCT06819007) tests T-DXd + bevacizumab maintenance.
Find Ovarian Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your BRCA/HRD status, histology, and treatment history.
Find Matching Trials
